Gainers
- MSP Recovery LIFW shares rose 18.9% to $0.24 during Monday's after-market session. At the close, MSP Recovery's trading volume reached 7.7 million shares. This is 22.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $78.8 million.
- ALX Oncology Holdings ALXO stock rose 17.46% to $5.65. Trading volume for this security closed at 50.4K, accounting for 31.9% of its average full-day volume over the last 100 days. The company's market cap stands at $232.5 million.
- SenesTech SNES shares moved upwards by 10.51% to $0.47. The company's market cap stands at $1.3 million.
- China Pharma Holding CPHI stock rose 8.81% to $0.15. The company's market cap stands at $1.7 million.
- Phio Pharma PHIO shares moved upwards by 7.89% to $1.64. The market value of their outstanding shares is at $3.6 million.
- GRI Bio GRI stock moved upwards by 7.87% to $1.78. The company's market cap stands at $5.2 million.
Losers
- Impel Pharmaceuticals IMPL stock decreased by 8.9% to $0.38 during Monday's after-market session. The company's market cap stands at $8.9 million.
- Acurx Pharmaceuticals ACXP stock decreased by 7.81% to $1.3. This security traded at a volume of 5.9 million shares come close, making up 16927.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.9 million.
- Connect Biopharma Hldgs CNTB stock fell 7.44% to $0.93. The market value of their outstanding shares is at $50.9 million.
- SmileDirectClub SDC shares decreased by 6.96% to $0.15. Trading volume for this security closed at 6.4 million, accounting for 292.9% of its average full-day volume over the last 100 days. The company's market cap stands at $20.0 million.
- Redhill Biopharma RDHL stock decreased by 6.59% to $0.43. The company's market cap stands at $2.4 million.
- Takeda Pharmaceutical TAK stock decreased by 5.83% to $14.39. The market value of their outstanding shares is at $44.7 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in